Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Point-of-Sale Rebates Gaining Traction In Employer-Sponsored Insurance

Executive Summary

Survey by National Business Group on Health also finds growing momentum behind use of copay accumulator programs.

You may also be interested in...



Pfizer Expects Rebate Reform By HHS Will Extend Quickly To Private Market

CEO Ian Read offers view of what’s ahead in US drug pricing reform based on his recent meeting with President Trump at the White House.

HHS Advancing Attack On Rebates With Proposal To Revoke Safe Harbor

Upcoming proposed rule could also provide new anti-kickback safe harbor to facilitate value-based contracts, as manufacturers and payers have urged.

UnitedHealthcare Will Apply About 80% Of Rebates At Point-Of-Sale

Insurer offers additional details on upcoming rebate program, including how it will protect contract confidentiality, and which members might use it the most.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS123674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel